Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Operations (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Cash from Operations for 11 consecutive years, with 52557000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 28.29% to 52557000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 302400000.0, a 14.33% increase, with the full-year FY2025 number at 302400000.0, up 14.33% from a year prior.
  • Cash from Operations was 52557000.0 for Q4 2025 at Iovance Biotherapeutics, up from 78702000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 52557000.0 in Q4 2025 to a low of 122279000.0 in Q1 2024.
  • A 3-year average of 84766416.67 and a median of 84026500.0 in 2023 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 31.48% in 2025; the steepest drop was 33.45% in 2025.
  • Iovance Biotherapeutics' Cash from Operations stood at 83970000.0 in 2023, then rose by 12.71% to 73296000.0 in 2024, then increased by 28.29% to 52557000.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Cash from Operations are 52557000.0 (Q4 2025), 78702000.0 (Q3 2025), and 67441000.0 (Q2 2025).